Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate

10/27/2020 | 03:25am EST

SEOUL, Oct 27 (Reuters) - South Korea's food and drug ministry said on Tuesday it had begun a preliminary review of a COVID-19 vaccine being developed by AstraZeneca PLC for potential fast-track approval.

The Ministry of Food and Drug Safety said in a statement that it had formed a screening team to review the vaccine candidate, with an application for formal approval expected in 90 days under its rapid approval programme for COVID-19 treatments and vaccines.

The team is reviewing the vaccine's non-clinical test data, the ministry said.

The ministry added that it had given a green light to some 26 clinical trials for COVID-19 treatments and vaccines as of Monday, by entities such as pharmaceutical companies Celltrion Inc and Genexine Inc, with seven completed and 19 ongoing.

(Reporting by Joyce Lee; Editing by Kirsten Donovan)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.41% 7825.18 Delayed Quote.2.54%
CELLTRION, INC. 1.80% 340000 End-of-day quote.87.85%
GENEXINE INC End-of-day quote.
All news about ASTRAZENECA PLC
05:25aFACTBOX : UK approves Pfizer-BioNTech COVID-19 vaccine: Who gets it first?
RE
05:10aUK approves Pfizer-BioNTech COVID-19 vaccine, first in the world
RE
04:33aNorth Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
04:13aPhilippines gives FDA emergency use powers for COVID-19 drugs, vaccines
RE
04:10aPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- 2nd Update
DJ
03:06aPfizer and BioNTech's Covid-19 Vaccine Wins U.K. Authorization -- Update
DJ
02:59aNorth Korean Hackers Are Said to Have Targeted Companies Working on Covid-19 ..
DJ
12/01Brazil sees one-dose, unfrozen vaccine as ideal for COVID-19 -official
RE
12/01Global equity markets jump, bonds dip, on hopes of vaccine-led recovery
RE
12/01IONIS PHARMACEUTICALS : announces AstraZeneca's initiation of the Phase 2b clini..
AQ
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 44,0x
Yield 2020 2,69%
Capitalization 137 B 137 B -
EV / Sales 2020 5,68x
EV / Sales 2021 4,95x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,91 $
Last Close Price 104,68 $
Spread / Highest target 48,5%
Spread / Average Target 16,5%
Spread / Lowest Target -36,9%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.54%137 451
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415